Previous 10 |
The healthcare sector has gained significant importance since the onset of the pandemic. Moreover, the industry is evolving with unique product launches and technological advancements. The healthcare sector has seen several IPOs this year. Healthcare companies 2seventy (TSVT), Regencell (RGC)...
New analyses from pivotal KarMMa study continue to show clinically meaningful health-related quality of life benefits and positive treatment experience with ABECMA, building upon growing body of evidence supporting the first and only approved CAR T cell therapy for multiple myeloma ...
2seventy bio (NASDAQ:TSVT): Q3 Net Loss of $60M Revenue of $19.3M (+4.9% Y/Y) beats by $10.76M. Press Release For further details see: 2seventy bio beats on revenue
– SC-DARIC33 IND accepted by FDA; Phase 1 study now enrolling 2seventy bio, Inc . (Nasdaq: TSVT), an emerging immuno-oncology company, today reported financial results and recent highlights for the third quarter ended September 30, 2021. “We launched 2s...
News, Short Squeeze, Breakout and More Instantly...
- Divestiture Supports Company Focus on Development and Commercialization of Abecma - 2seventy bio, Inc . (Nasdaq: TSVT), announced today the completion of an asset purchase agreement (“APA”) by Novo Nordisk. Under the terms of the APA, Novo Nordisk has acquired th...
2024-06-06 06:15:03 ET Goldman Sachs analyst issues SELL recommendation for TSVT on June 6, 2024 05:06AM ET. The previous analyst recommendation was Buy. TSVT was trading at $4.56 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current an...
2seventy bio, Inc . (Nasdaq: TSVT) will announce its first quarter 2024 financial results on Wednesday, May 8, 2024. A conference call and webcast will be held at 8:00 a.m. ET. Participants can access the conference call live via webcast which will be available on the Investors and Media pa...